Astrana Health (NASDAQ:ASTH) Trading Down 6.1% Following Analyst Downgrade

Astrana Health, Inc. (NASDAQ:ASTH) was down 6.1% during mid-day trading on Monday after BTIG Research lowered their price target on the stock from $50.00 to $45.00. BTIG Research currently has a buy rating on the stock. Astrana Health traded as low as $23.88 and last traded at $23.9610. Approximately 77,878 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 345,901 shares. The stock had previously closed at $25.53.

Other research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Astrana Health in a research report on Wednesday, October 8th. Zacks Research raised shares of Astrana Health from a “strong sell” rating to a “hold” rating in a research report on Friday, October 10th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $47.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Astrana Health by 4.5% in the 1st quarter. Vanguard Group Inc. now owns 4,898,992 shares of the company’s stock worth $151,918,000 after purchasing an additional 213,033 shares in the last quarter. SteelPeak Wealth LLC lifted its holdings in Astrana Health by 7.8% during the third quarter. SteelPeak Wealth LLC now owns 579,937 shares of the company’s stock worth $16,441,000 after acquiring an additional 41,761 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Astrana Health by 6.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 499,529 shares of the company’s stock worth $15,490,000 after purchasing an additional 28,200 shares during the last quarter. Diamond Hill Capital Management Inc. grew its stake in Astrana Health by 33.0% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 361,264 shares of the company’s stock valued at $10,242,000 after purchasing an additional 89,733 shares during the period. Finally, Invesco Ltd. grew its stake in Astrana Health by 13.0% in the 1st quarter. Invesco Ltd. now owns 292,043 shares of the company’s stock valued at $9,056,000 after purchasing an additional 33,523 shares during the period. 52.77% of the stock is owned by institutional investors and hedge funds.

Astrana Health Stock Down 5.8%

The company has a market capitalization of $1.35 billion, a P/E ratio of 47.13, a PEG ratio of 0.90 and a beta of 0.80. The stock has a 50 day moving average price of $30.44 and a 200 day moving average price of $27.89. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.59 and a current ratio of 1.59.

Astrana Health (NASDAQ:ASTH) last released its earnings results on Wednesday, January 10th. The company reported $0.50 earnings per share (EPS) for the quarter. Astrana Health had a return on equity of 3.43% and a net margin of 1.04%.The business had revenue of $317.00 million during the quarter. Equities research analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.